heart block [SEP] Complete heart block following a single dose of trazodone.

Heart Block [SEP] Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE


trazodone [SEP] Complete heart block following a single dose of trazodone.

Trazodone [SEP] A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major d


trazodone [SEP] Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block. The case illustrates


heart block [SEP] single starting dose of trazodone, a patient developed complete heart block. The case illustrates that, despite the results of earlier stud


Quinidine phenylethylbarbiturate [SEP] Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. A case report.

phenobarbital quinidine [SEP]


hepatitis [SEP] Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. A case report.

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


hepatitis [SEP] the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month adm


quinidine phenylethylbarbiturate [SEP] rd trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate. After delivery, the patient underwent orthotopic liver transpl

phenobarbital quinidine [SEP]


Quinidine [SEP] nt was in good condition 16 months after liver transplantation. Quinidine itself or phenylethylbarbiturate may be responsible for fulmina

Quinidine [SEP] An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the


phenylethylbarbiturate [SEP] er of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate. After delivery, the patient underwent orthotopic liver transpl

phenobarbital quinidine [SEP]


flank pain [SEP] The epidemiology of the acute flank pain syndrome from suprofen.

Flank Pain [SEP] Pain emanating from below the RIBS and above the ILIUM.


suprofen [SEP] The epidemiology of the acute flank pain syndrome from suprofen.

Suprofen [SEP] An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an a


Suprofen [SEP] Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in ear


flank pain [SEP] lgesic agent. Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons u


suprofen [SEP] ho had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome. Case pa


hay fever [SEP] dds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9)

Rhinitis, Allergic, Seasonal [SEP] Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCH


asthma [SEP] ; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to partic

Asthma [SEP] A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway


alcohol [SEP] ecially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible

Ethanol [SEP] A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bacterici


ibuprofen [SEP] young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a hist

Ibuprofen [SEP] A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.


renal disease [SEP] e of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increa

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


kidney stones [SEP] (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent inc

Kidney Calculi [SEP] Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most conta


gout [SEP] xisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposu

Gout [SEP] Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and ar


uric acid [SEP] ism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.

Uric Acid [SEP] An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product o


Hemolytic-uremic syndrome [SEP] Hemolytic-uremic syndrome associated with ingestion of quinine.

Hemolytic-Uremic Syndrome [SEP] A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by


quinine [SEP] Hemolytic-uremic syndrome associated with ingestion of quinine.

Quinine [SEP] An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extr


Hemolytic-uremic syndrome [SEP] Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, wi


quinine [SEP] Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previo


prednisone [SEP] ence of quinine. Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole. The patients have all regained some

Prednisone [SEP] A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in t


aspirin [SEP] ine. Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole. The patients have all regained some degree o

Aspirin [SEP] The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties a


dipyridamole [SEP] t has included use of plasma exchange, prednisone, aspirin, and dipyridamole. The patients have all regained some degree of renal function.

Dipyridamole [SEP] A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dip


Quinine [SEP] t or spontaneous resolution is responsible for the improvement. Quinine-associated hemolytic-uremic syndrome probably occurs more often


hemolytic-uremic syndrome [SEP] solution is responsible for the improvement. Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized. It is important


pyeloureteritis cystica [SEP] The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.

Pyelitis [SEP] Inflammation of the KIDNEY PELVIS and KIDNEY CALICES where urine is collected before discharge, but does not involve the renal p


infection [SEP]  of pyeloureteritis cystica has long been attributed to chronic infection and inflammation. A case is presented that is unique in that th

Infection [SEP] Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.


inflammation [SEP] ritis cystica has long been attributed to chronic infection and inflammation. A case is presented that is unique in that the acute onset and

Inflammation [SEP] A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions


heparin [SEP] s patient. The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapid

Heparin [SEP] A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges


thrombophlebitis [SEP] quent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation. The rate

Thrombophlebitis [SEP] Inflammation of a vein associated with a blood clot (THROMBUS).


submucosal hemorrhage [SEP] pful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.

Hemorrhage [SEP] Bleeding or escape of blood from a vessel.


hepatoma [SEP] Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.

Carcinoma, Hepatocellular [SEP] A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indisti


alpha-benzene hexachloride [SEP] oxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.

Lindane [SEP] An organochlorine insecticide that has been used as a pediculicide and a scabicide. It has been shown to cause cancer.


hepatomas [SEP] Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by


liver lesions [SEP] Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were exam

Liver Failure [SEP] Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum leve


alpha-benzene hexachloride [SEP] rplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically. Alt


tumors [SEP] ically. Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor c

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


tumor [SEP] ically. Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor


ethyl-alpha-p-chlorophenoxyisobutyrate [SEP] rable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes. At the 16th week of carcinog

beta-diethylaminoethyl alpha-4-chlorophenoxyisobutyrate [SEP]


Quinidine [SEP] Quinidine hepatitis.

Quinidine [SEP] An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the


hepatitis [SEP] Quinidine hepatitis.

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


quinidine [SEP] Long-term administration of quinidine was associated with persistent elevation of serum concentration


lactic acid [SEP] ated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase. Liver biopsy showed ac

Lactic Acid [SEP] A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent


hepatitis [SEP] drogenase, and alkaline phosphatase. Liver biopsy showed active hepatitis. Discontinuance of quinidine therapy led to normalization of li


hepatotoxicity [SEP] ydrogenase values. We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver bio


hepatic toxicity [SEP] rt also suggests that, even after long-term administration, the hepatic toxicity is reversible.


Cholesteryl hemisuccinate [SEP] Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminop

cholesteryl succinate [SEP]


acetaminophen [SEP] isuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine

Acetaminophen [SEP] Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but


adriamycin [SEP] tment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


carbon tetrachloride [SEP] ts rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.

Carbon Tetrachloride [SEP] A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic


chloroform [SEP] xic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.

Chloroform [SEP] A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its susp


galactosamine [SEP] acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.

Galactosamine [SEP]


cholesteryl hemisuccinate [SEP] In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect r

cholesteryl succinate [SEP]


hepatotoxic [SEP] CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4). To further our understa


carbon tetrachloride [SEP] also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4). To further our understanding of the mechanism of CS cyt


CCl4 [SEP] tect rats from the hepatotoxic effects of carbon tetrachloride (CCl4). To further our understanding of the mechanism of CS cytoprote


gamma-cholesteryloxybutyric acid [SEP] tive abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon te

4-(cholesteryloxy)butyric acid [SEP]


acetaminophen [SEP] f CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosa


adriamycin [SEP] esteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced


chloroform [SEP] SE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity. The results of these studi


galactosamine [SEP] aminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity. The results of these studies demonstrated tha

Galactosamine [SEP]


toxicity [SEP] -, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity. The results of these studies demonstrated that CS-mediated pro

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


CHCl3 [SEP] significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and pr


cardiotoxic [SEP] nophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration. Maximal CS-mediated prote

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


hepatotoxicity [SEP] iate (in light of the protection observed against galactosamine hepatotoxicity). However, based on the data presented, we can not exclude the


cyclophosphamide [SEP] DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission indu

Cyclophosphamide [SEP] Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to fo


bortezomib [SEP] definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly di

bortezomib [SEP]


dexamethasone [SEP] for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myelom

Dexamethasone [SEP] An anti-inflammatory 9-fluoro-glucocorticoid.


myeloma [SEP] hasone for remission induction in patients with newly diagnosed myeloma.

Multiple Myeloma [SEP] A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia,


cyclophosphamide [SEP] linical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction t


bortezomib [SEP] te the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell trans

bortezomib [SEP]


dexamethasone [SEP] ded dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for you


multiple myeloma [SEP]  cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of


MM [SEP] ion for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bort


gastrointestinal toxicities [SEP] isease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in c

Gastrointestinal Diseases [SEP] Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.


neuropathy [SEP] s were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclop

Nervous System Diseases [SEP] Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, periph


telmisartan [SEP] of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults w

telmisartan [SEP]


amlodipine [SEP] and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hy

Amlodipine [SEP] A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.


hypertension [SEP] ne versus amlodipine monotherapy in Indian adults with stage II hypertension.

Hypertension [SEP] Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is c


telmisartan [SEP] icacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg mon

telmisartan [SEP]


amlodipine [SEP] ty of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adu


hypertension [SEP] ine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension. METHODS: This comparative, Phase III, 12-week, multicenter, pr


edema [SEP] ent groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]). Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


cough [SEP]  the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0%

Cough [SEP] A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective


headache [SEP] ences did not reach statistical significance. The incidences of headache, dizziness, and diarrhea were similar between the 2 groups. CON

Headache [SEP] The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACH


dizziness [SEP] not reach statistical significance. The incidences of headache, dizziness, and diarrhea were similar between the 2 groups. CONCLUSIONS: A

Dizziness [SEP] An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.


diarrhea [SEP] stical significance. The incidences of headache, dizziness, and diarrhea were similar between the 2 groups. CONCLUSIONS: Among these Ind

Diarrhea [SEP] An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of wa


Cutaneous leucocytoclastic vasculitis [SEP] Cutaneous leucocytoclastic vasculitis associated with oxacillin.

Vasculitis, Leukocytoclastic, Cutaneous [SEP] Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or othe


oxacillin [SEP] Cutaneous leucocytoclastic vasculitis associated with oxacillin.

Oxacillin [SEP] An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.


oxacillin [SEP] A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, devel


Staphylococcus aureus bacteremia [SEP] -old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpu

Staphylococcal Infections [SEP] Infections with bacteria of the genus STAPHYLOCOCCUS.


bacteremia [SEP] ed with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpu

Bacteremia [SEP] The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestati


renal failure [SEP] one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.

Renal Insufficiency [SEP] Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain


purpuric lesions [SEP] remia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin

Purpura [SEP] Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the si


Necrotic [SEP]  and diffuse, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin biopsies showed findin

Necrosis [SEP] The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrol


blisters [SEP] use, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin biopsies showed findings diagno

Blister [SEP] Visible accumulations of fluid within or beneath the epidermis.


leucocytoclastic vasculitis [SEP] ted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with cortic


Oxacillin [SEP] sies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with corticosteroids.


corticosteroids [SEP] ulitis. Oxacillin was discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function retu

Adrenal Cortex Hormones [SEP]


rash [SEP]  discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function returned to no

Exanthema [SEP] Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with sim


Leucocytoclastic vasculitis [SEP] peared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often acc


purpura [SEP] ned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, a


abdominal pain [SEP]  palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement. Etiologic factors or associ

Abdominal Pain [SEP] Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue inju


arthralgia [SEP] a of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement. Etiologic factors or associated disorde

Arthralgia [SEP] Pain in the joint.


renal involvement [SEP] xtremities often accompanied by abdominal pain, arthralgia, and renal involvement. Etiologic factors or associated disorders include infections,

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


infections [SEP]  involvement. Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia. However,

Infection [SEP] Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.


collagen vascular disease [SEP] actors or associated disorders include infections, medications, collagen vascular disease and neoplasia. However, in half of the cases no etiologic facto

Collagen Diseases [SEP] Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus,


neoplasia [SEP]  include infections, medications, collagen vascular disease and neoplasia. However, in half of the cases no etiologic factor is identifie

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


corticosteroid [SEP] ulitis. Oxacillin was discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function ret

Adrenal Cortex Hormones [SEP]


Naloxazone [SEP] Naloxazone pretreatment modifies cardiorespiratory, temperature, and behav

naloxazone [SEP]


morphine [SEP] ifies cardiorespiratory, temperature, and behavioral effects of morphine.

Morphine [SEP] The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central


morphine [SEP] Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an


naloxazone [SEP] se of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors. Pretreat

naloxazone [SEP]


analgesia [SEP] rs. Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminate

Pain Insensitivity, Congenital [SEP] A syndrome characterized by indifference to PAIN despite the ability to distinguish noxious from non-noxious stimuli. Absent cor


catalepsy [SEP] tment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affi

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


hypothermia [SEP] oxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in

Hypothermia [SEP] Lower than normal body temperature, especially in warm-blooded animals.


hypotension [SEP] eover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardi

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


respiratory depression [SEP] e significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected. Result

Respiratory Insufficiency [SEP] Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)


bradycardia [SEP] ypotension and respiratory depression, whereas morphine-induced bradycardia was less affected. Results indicate that subpopulations of mu r

Bradycardia [SEP] Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. Th


Dexrazoxane [SEP] Dexrazoxane protects against myelosuppression from the DNA cleavage-enhanci

Dexrazoxane [SEP] The (+)-enantiomorph of razoxane.


myelosuppression [SEP] Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubici

Bone Marrow Diseases [SEP]


etoposide [SEP]  against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Etoposide [SEP] A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a co


daunorubicin [SEP] suppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Daunorubicin [SEP] A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of L


doxorubicin [SEP] DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


anthracyclines [SEP] PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposi

Anthracyclines [SEP] Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daun


daunorubicin [SEP] PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent


doxorubicin [SEP] PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-en


epipodophyllotoxin [SEP] URPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are wide

Podophyllotoxin [SEP] A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if take


etoposide [SEP] yclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in


myelosuppression [SEP] ncing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is

Bone Marrow Diseases [SEP]


cardiac toxicity [SEP] widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for prot

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


Dexrazoxane [SEP] however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-


ICRF-187 [SEP] osuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced ca


anthracycline [SEP] PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etopos


cardiotoxicity [SEP] 87) is recommended for protection against anthracycline-induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the hema


hematologic toxicity [SEP] city. EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three struc

Hematologic Diseases [SEP] Disorders of the blood and blood forming tissues.


dexrazoxane [SEP] ead use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers w


weight loss [SEP] LTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their a

Weight Loss [SEP] Decrease in existing BODY WEIGHT.


cytotoxicity [SEP] neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin. CONCLUSION: Although our findings support the

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


metastases [SEP]  the use of dexrazoxane. Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing wi

Neoplasm Metastasis [SEP] The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.


aniracetam [SEP] Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

aniracetam [SEP]


Ro 13-5057 [SEP] Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

aniracetam [SEP]


impaired learning [SEP] Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

Learning Disorders [SEP] Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to


aniracetam [SEP] The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various

aniracetam [SEP]


Ro 13-5057 [SEP] The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of exp

aniracetam [SEP]


1-anisoyl-2-pyrrolidinone [SEP] The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognit

aniracetam [SEP]


impaired cognitive functions [SEP] 2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following eff

Cognition Disorders [SEP] Disturbances in the mental process related to thinking, reasoning, and judgment.


hypercapnia [SEP] o learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats)

Hypercapnia [SEP] A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.


scopolamine [SEP] ession; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) co

Scopolamine Hydrobromide [SEP] An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics l


amnesia [SEP] omplete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against a

Amnesia [SEP] Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMN


chloramphenicol [SEP] eficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5

Chloramphenicol [SEP] An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relativel


cycloheximide [SEP] e avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when

Cycloheximide [SEP] Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation duri


Piracetam [SEP] ctivity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another pyrrolidinone derivative was used for comparison. It w

Piracetam [SEP] A compound suggested to be both a nootropic and a neuroprotective agent.


pyrrolidinone [SEP] The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognit

Pyrrolidinones [SEP] A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermed


Nicotine [SEP] Nicotine potentiation of morphine-induced catalepsy in mice.

Nicotine [SEP] Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimu


morphine [SEP] Nicotine potentiation of morphine-induced catalepsy in mice.

Morphine [SEP] The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central


catalepsy [SEP] Nicotine potentiation of morphine-induced catalepsy in mice.

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


nicotine [SEP] In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated


catalepsy [SEP] In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated. Morphine bu


morphine [SEP]  the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated. Morphine but not nicotine induc


Morphine [SEP] n catalepsy induced by morphine in mice have been investigated. Morphine but not nicotine induced a dose-dependent catalepsy. The respon


atropine [SEP]  was potentiated by nicotine. Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced cata

Atropine [SEP] An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isome


naloxone [SEP] tiated by nicotine. Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy indu

Naloxone [SEP] A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid recepto


mecamylamine [SEP] nicotine. Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combi

Mecamylamine [SEP] A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine h


hexamethonium [SEP] itoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine

Hexamethonium [SEP] A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gast


cardiotoxicity [SEP] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxor

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


doxorubicin [SEP] icity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


cyclophosphamide [SEP] ved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in

Cyclophosphamide [SEP] Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to fo


breast cancer [SEP] clophosphamide in a randomized, multicenter trial of metastatic breast cancer.

Breast Neoplasms [SEP] Tumors or cancer of the human BREAST.


Myocet [SEP] PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan


doxorubicin [SEP] PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in comb


cyclophosphamide [SEP] e Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providin


cardiotoxicity [SEP] ination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line tre


breast cancer [SEP] arable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC). PATIENTS AND METHODS: Two hundred ninety-seven patients


MBC [SEP] r efficacy in first-line treatment of metastatic breast cancer (MBC). PATIENTS AND METHODS: Two hundred ninety-seven patients with


toxicity [SEP] n with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line tre

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


Cardiotoxicity [SEP] ery 3 weeks until disease progression or unacceptable toxicity. Cardiotoxicity was defined by reductions in left-ventricular ejection fraction


congestive heart failure [SEP] ssessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF). Antitumor efficacy was assessed by objective tumor respo

Heart Failure [SEP] A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Hear


CHF [SEP] ed radionuclide angiography scans, or congestive heart failure (CHF). Antitumor efficacy was assessed by objective tumor response r


tumor [SEP] duces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (M

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


neutropenia [SEP]  hazard ratio, 5.04). MC patients also experienced less grade 4 neutropenia. Antitumor efficacy of MC versus AC was comparable: objective r

Neutropenia [SEP] A decrease in the number of NEUTROPHILS found in the blood.


BN 52021 [SEP] ive effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.

ginkgolide B [SEP]


bupivacaine [SEP]  a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.

Bupivacaine [SEP] A widely used local anesthetic agent.


cardiovascular impairments [SEP] -activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.

Cardiovascular Diseases [SEP] Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.


bupivacaine [SEP] Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of me


decrease of mean arterial blood pressure (MBP) [SEP] ic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


BN 52021 [SEP] ion of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i

ginkgolide B [SEP]


decrease of MBP [SEP] e bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR. In contrast, doses of 1 mg/kg BN 52021 given 30 min bef


cardiovascular toxicity [SEP] 2021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity. Thus, consistent with its direct effect on heart, PAF appears


cardiovascular alterations [SEP] t on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.

Cardiovascular Abnormalities [SEP] Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS.


Benzylacyclouridine [SEP] Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impa

5-benzylacyclouridine [SEP]


azidothymidine [SEP] Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human imm

Zidovudine [SEP] A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modific


marrow suppression [SEP] Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activit

Bone Marrow Diseases [SEP]


immunodeficiency [SEP] ine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.

Immunologic Deficiency Syndromes [SEP] Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.


uridine [SEP] Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (A

Uridine [SEP]


Urd [SEP] Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-i

Uridine [SEP]


azidothymidine [SEP] ations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progen


AZT [SEP] e (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor


immunodeficiency [SEP] macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity. Because of the clinical toxicities associ


toxicities [SEP]  immunodeficiency virus (HIV) activity. Because of the clinical toxicities associated with chronic Urd administration, the ability of benz


benzylacyclouridine [SEP] ties associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was

5-benzylacyclouridine [SEP]


BAU [SEP] chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was asse

5-benzylacyclouridine [SEP]


anemia [SEP] ty of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed. This agent inhibits Urd catabolism

Anemia [SEP] A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.


leukopenia [SEP] lacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed. This agent inhibits Urd catabolism and, in vivo,

Leukopenia [SEP]


toxicity [SEP] ntration of Urd in a dose-dependent manner, without Urd-related toxicity. In mice rendered anemic and leukopenic by the administration o


anemic [SEP] ependent manner, without Urd-related toxicity. In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drin


leukopenic [SEP] nner, without Urd-related toxicity. In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5

Leukopenia [SEP]


marrow toxicity [SEP]  from the onset of drug administration, BAU reduced AZT-induced marrow toxicity. In vitro, at a concentration of 100 mumol/L, BAU possesses min

Bone Marrow Diseases [SEP]


Cyclophosphamide [SEP] Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral ap


cystitis [SEP] Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new m

Cystitis [SEP] Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful


visceral pain [SEP] ly-moving conscious rats: behavioral approach to a new model of visceral pain.

Visceral Pain [SEP] Pain originating from internal organs (VISCERA) associated with autonomic phenomena (PALLOR; SWEATING; NAUSEA; and VOMITING). It


visceral pain [SEP] PURPOSE: To develop a model of visceral pain in rats using a behavioral approach. Cyclophosphamide (CP), an


Cyclophosphamide [SEP] p a model of visceral pain in rats using a behavioral approach. Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on th


CP [SEP] ral pain in rats using a behavioral approach. Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bl


acrolein [SEP] c effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis. MATERIALS AND METHODS: CP was adm

Acrolein [SEP]


cystitis [SEP]  through its main toxic metabolite acrolein, was used to induce cystitis. MATERIALS AND METHODS: CP was administered at doses of 50, 100


morphine [SEP] le rats, and their behavior observed and scored. The effects of morphine (0.5 to 4 mg./kg. i.v.) on CP-induced behavioral modifications

Morphine [SEP] The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central


naloxone [SEP] havioral modifications were tested administered alone and after naloxone (1 mg./kg. s.c.). In addition, 90 minutes after CP injection, t

Naloxone [SEP] A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid recepto


Morphine [SEP] rease, closing of the eyes and occurrence of specific postures. Morphine dose-dependently reversed these behavioral disorders. A dose of


behavioral disorders [SEP]  of specific postures. Morphine dose-dependently reversed these behavioral disorders. A dose of 0.5 mg./kg. produced a reduction of almost 50% of th

Mental Disorders [SEP] Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of tho


edema [SEP] cations of the bladder wall, such as chorionic and muscle layer edema, were observed. In female rats, CP 200 mg./kg. i.p. produced th

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


painful syndromes [SEP] mmatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.

Pain [SEP] An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.


Hyperalgesia [SEP] Hyperalgesia and myoclonus in terminal cancer patients treated with continuo

Hyperalgesia [SEP] An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCIC


myoclonus [SEP] Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous

Myoclonus [SEP] Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscle


cancer [SEP] Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


morphine [SEP] in terminal cancer patients treated with continuous intravenous morphine.


cancer [SEP] Eight cancer patients in the terminal stages of the disease treated with hig


morphine [SEP] al stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. All cases were retrospectively sampled


hyperalgesia [SEP] sease treated with high doses of intravenous morphine developed hyperalgesia. All cases were retrospectively sampled from three different ho


hyperesthesia [SEP]  Copenhagen. Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus. In 3 patients a

Hyperesthesia [SEP] Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.


myoclonus [SEP] ralgesia and hyperesthesia which in 2 cases were accompanied by myoclonus. In 3 patients a pre-existing neuralgia increased to excruciati


neuralgia [SEP] ses were accompanied by myoclonus. In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myo

Neuralgia [SEP] Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.


vancomycin [SEP] A prospective study of adverse reactions associated with vancomycin therapy.

Vancomycin [SEP] Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wal


vancomycin [SEP] A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16-month period


Vancomycin [SEP] as conducted in 54 consecutive patients over a 16-month period. Vancomycin was curative in 95% of 43 patients with proven infection. Drugs


infection [SEP] riod. Vancomycin was curative in 95% of 43 patients with proven infection. Drugs were ceased in six patients because of adverse reactions

Infection [SEP] Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.


thrombophlebitis [SEP]  vancomycin was considered the likely cause. Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50),

Thrombophlebitis [SEP] Inflammation of a vein associated with a blood clot (THROMBUS).


rash [SEP] cause. Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and

Exanthema [SEP] Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with sim


nephrotoxicity [SEP]  included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patie

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


proteinuria [SEP]  (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometr

Proteinuria [SEP] The presence of proteins in the urine, an indicator of KIDNEY DISEASES.


ototoxicity [SEP]  (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry). Thrombophlebitis occur

Hearing Disorders [SEP] Conditions that impair the transmission of auditory impulses and information from the level of the ear to the temporal cortices,


Thrombophlebitis [SEP] of 50) and ototoxicity (1 of 11 patients tested by audiometry). Thrombophlebitis occurred only with infusion through peripheral cannulae; nephro


aminoglycoside [SEP] toxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin. We conclude that vancomycin, administered appr

Aminoglycosides [SEP] Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTIC


infections [SEP] nistered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.


dopamine [SEP] Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


catalepsy [SEP] Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


catalepsy [SEP] 1. The catalepsy induced by dopamine antagonists has been tested and the possibl


dopamine [SEP] 1. The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes


Dopamine [SEP] ible dopamine subtypes involved in catalepsy was determined. 2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antago


fluphenazine [SEP] es involved in catalepsy was determined. 2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced c

Fluphenazine [SEP] A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.


SCH 23390 [SEP] determined. 2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy. The effect of fl

SCH 23390 [SEP]


sulpiride [SEP] gonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy. The effect of fluphenazine and sulpiride was

Sulpiride [SEP] A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid.


SKF 38393 [SEP] sulpiride did not induce catalepsy potentiation. 3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fl

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine [SEP] A selective D1 dopamine receptor agonist used primarily as a research tool.


quinpirole [SEP] catalepsy potentiation. 3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or s

Quinpirole [SEP] A dopamine D2/D3 receptor agonist.


Dextran [SEP] Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation

Dextrans [SEP] A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagu


etodolac [SEP] Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.

Etodolac [SEP] A nonsteroidal anti-inflammatory agent with potent analgesic and antiarthritic properties. It has been shown to be effective in


Etodolac [SEP] Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug. A b


E [SEP] Etodolac (E), is a non-narcotic analgesic and antiinflammatory dr


dextran [SEP] ic analgesic and antiinflammatory drug. A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextra


etodolac [SEP] polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and r


acetic acid [SEP] nalgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw e

Acetic Acid [SEP] Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as


writhing [SEP] lammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respe

Pain [SEP] An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.


carrageenan [SEP] ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively. In comparison to con

Carrageenan [SEP] A water-soluble extractive mixture of sulfated polysaccharides from RED ALGAE. Chief sources are the Irish moss CHONDRUS CRISPUS


edema [SEP] d induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively. In comparison to control, E and ED1-ED4 sh

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


Hypersensitivity [SEP] Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.

Drug Hypersensitivity [SEP] Immunologically mediated adverse reactions to medicinal substances used legally or illegally.


myocarditis [SEP] Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.

Myocarditis [SEP] Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCY


hypertrophic cardiomyopathy [SEP] Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.

Cardiomyopathy, Hypertrophic [SEP] A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYP


eosinophilic [SEP] The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy. The 47-ye

Eosinophilia [SEP] Abnormal increase of EOSINOPHILS in the blood, tissues or organs.


myocarditis [SEP] The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy. The 47-year-old femal


hypertrophic cardiomyopathy [SEP] eport describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy. The 47-year-old female patient, known to have hypertrophic car


biventricular failure [SEP] t, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other dru

Ventricular Dysfunction [SEP] A condition in which HEART VENTRICLES exhibit impaired function.


dobutamine [SEP] mitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transpl

Dobutamine [SEP] A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CA


left ventricular dysfunction [SEP] nsplantation. On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation. Th

Ventricular Dysfunction, Left [SEP] A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; M


mitral regurgitation [SEP]  ventricular dysfunction with regional variability and moderate mitral regurgitation. The recipient's heart showed the features of apical hypertroph

Mitral Valve Insufficiency [SEP] Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mi


Myocarditis [SEP] ophic cardiomyopathy and myocarditis with abundant eosinophils. Myocarditis is rare and eosinophilic myocarditis is rarer. It is likely tha


hypersensitivity [SEP] re and eosinophilic myocarditis is rarer. It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion t


Eosinophilic [SEP] philic) myocarditis was related to dobutamine infusion therapy. Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2%


All- trans-retinoic acid [SEP] All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic l

Tretinoin [SEP] An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic aci


erythema nodosum [SEP] All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.

Erythema Nodosum [SEP] An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are


acute promyelocytic leukemia [SEP] - trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.

Leukemia, Promyelocytic, Acute [SEP] An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCUL


Erythema nodosum [SEP] Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promy


all- trans-retinoic acid [SEP] Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare. We


ATRA [SEP] Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare. We descri


acute promyelocytic leukemia [SEP] ema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare. We describe four patients with classic APL


APL [SEP] l- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare. We describe four patients with classic APL who d


erythema nodosum [SEP]  rare. We describe four patients with classic APL who developed erythema nodosum during ATRA therapy. Fever and subsequent multiple painful eryt


Fever [SEP] classic APL who developed erythema nodosum during ATRA therapy. Fever and subsequent multiple painful erythematous nodules over extre

Fever [SEP] An abnormal elevation of body temperature, usually as a result of a pathologic process.


painful [SEP] hema nodosum during ATRA therapy. Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D1


erythematous nodules [SEP] osum during ATRA therapy. Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectiv


steroids [SEP] nt with erythema nodosum. All patients received short course of steroids. Fever subsided rapidly and the skin lesions regressed complete

Steroids [SEP] A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precurso


steroid [SEP] nt with erythema nodosum. All patients received short course of steroids. Fever subsided rapidly and the skin lesions regressed complet


heparin [SEP] Delayed-onset heparin-induced thrombocytopenia.

Heparin [SEP] A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges


thrombocytopenia [SEP] Delayed-onset heparin-induced thrombocytopenia.

Thrombocytopenia [SEP] A subnormal level of BLOOD PLATELETS.


Heparin [SEP] BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin ex


thrombocytopenia [SEP] BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without a


heparin [SEP] D: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli. Del


venous thromboemboli [SEP]  to 12 days after heparin exposure, with or without arterial or venous thromboemboli. Delayed recognition and treatment of heparin-induced thrombocy

Venous Thromboembolism [SEP] Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.


thromboembolic [SEP] d thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectiv

Thromboembolism [SEP] Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.


thromboembolism [SEP]  MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, a


Thromboemboli [SEP] he hospital (median, day 14) with thromboembolic complications. Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial


pulmonary emboli [SEP] c complications. Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both. Platelet counts were mildly

Pulmonary Embolism [SEP] Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.


warfarin [SEP] ents), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients). Three patients died. CONCLUSIONS: Delayed-onset

Warfarin [SEP] An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the


Valsartan [SEP] Valsartan, a new angiotensin II antagonist for the treatment of essential

valsartan [SEP]


angiotensin II [SEP] Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a compa

Angiotensin II [SEP] An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino aci


hypertension [SEP]  a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodip

Hypertension [SEP] Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is c


amlodipine [SEP] tension: a comparative study of the efficacy and safety against amlodipine.

Amlodipine [SEP] A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.


angiotensin II [SEP] OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. ME


valsartan [SEP] e antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred six

valsartan [SEP]


amlodipine [SEP] angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild t


hypertension [SEP] One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal numbe


edema [SEP] ts were well tolerated. The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


dihydropyridine [SEP] ated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.

1,4-dihydropyridine [SEP]


calcium [SEP] ffects characteristic of this comparator class, dihydropyridine calcium antagonists.

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


KF17837 [SEP] KF17837: a novel selective adenosine A2A receptor antagonist with antic

KF 17837 [SEP]


adenosine [SEP] KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.

Adenosine [SEP] A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles i


KF17837 [SEP] KF17837 is a novel selective adenosine A2A receptor antagonist. Oral ad

KF 17837 [SEP]


adenosine [SEP] KF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 1


cataleptic [SEP] F17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


CGS 21680 [SEP] entricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduc

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine [SEP]


catalepsy [SEP] crograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg


haloperidol [SEP] dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticatal

Haloperidol [SEP] A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoa


reserpine [SEP] uced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dos

Reserpine [SEP] An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into st


L-3,4-dihydroxyphenylalanine [SEP] otentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). The

Levodopa [SEP] The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can b


L-DOPA [SEP] effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These resul


benserazide [SEP] se of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a ce

Benserazide [SEP] An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatm


parkinsonism [SEP] . Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.

Parkinson Disease, Secondary [SEP] Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected co


fluvoxamine [SEP] Some central effects of repeated treatment with fluvoxamine.

Fluvoxamine [SEP] A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.


fluvoxamine [SEP] We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects


serotonin [SEP]  the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and

Serotonin [SEP] A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily i


methoxamine [SEP] uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "behavioral despair" test. A

Methoxamine [SEP] An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.


amphetamine [SEP] daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity. The hyperactivity induced by nomifensine

Amphetamine [SEP] A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blockin


hyperactivity [SEP] otentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity. The hyperactivity induced by nomifensine in mice remained unaf

Hyperkinesis [SEP] Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.


nomifensine [SEP] amphetamine-induced hyperactivity. The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine. The stimulation of

Nomifensine [SEP] An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of


citalopram [SEP] ndicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also

Citalopram [SEP] A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in redu


congestive heart failure [SEP] Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case re

Heart Failure [SEP] A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Hear


amiodarone [SEP] Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.

Amiodarone [SEP] An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibitin


myxedemic [SEP]  congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.

Myxedema [SEP] A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and


coma [SEP] e heart failure patient on amiodarone presenting with myxedemic coma: a case report.

Coma [SEP] A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Com


myxedema [SEP] This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patien


coma [SEP] This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient wit


amiodarone [SEP] This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive hear


hypothyroidism [SEP]  a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF). To our

Hypothyroidism [SEP] A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL


congestive heart failure [SEP] y to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF). To our knowledge and after reviewing the literature ther


CHF [SEP] pothyroidism in a patient with severe congestive heart failure (CHF). To our knowledge and after reviewing the literature there is


Myxedema [SEP] se report of myxedema coma during long term amiodarone therapy. Myxedema coma is a life threatening condition that carries a mortality r


thyroxine [SEP] s 20% with treatment. The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF

Thyroxine [SEP] The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) an


T4 [SEP] treatment. The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF on a


tri-iodo-thyronine [SEP] ition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbid

Triiodothyronine [SEP] A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most


T3 [SEP] h intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbidity


hypotension [SEP] spect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


weakness [SEP] inical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.

Muscle Weakness [SEP] A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be character


startle [SEP] Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drug

Reflex, Abnormal [SEP] An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased,


startle [SEP] RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the no


anxiety [SEP] The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect. In c

Anxiety Disorders [SEP] Persistent and disabling ANXIETY.


yohimbine [SEP] rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpi

Yohimbine [SEP] A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECT


5-HT [SEP] alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/

Serotonin [SEP] A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily i


m-chlorophenylpiperazine [SEP] gonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pe

1-(3-chlorophenyl)piperazine [SEP]


mCPP [SEP] mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylen

1-(3-chlorophenyl)piperazine [SEP]


GABA [SEP] or agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg)

gamma-Aminobutyric Acid [SEP] The most common inhibitory neurotransmitter in the central nervous system.


pentylenetetrazole [SEP] ne (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or

Pentylenetetrazole [SEP] A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-comp


PTZ [SEP] kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.


glomerulonephritis [SEP] neutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.

Glomerulonephritis [SEP] Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including anti


sulphasalazine [SEP] -ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.

Sulfasalazine [SEP] A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabol


ulcerative colitis [SEP] A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary

Colitis, Ulcerative [SEP] Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, th


red eyes [SEP] A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after

Eye Diseases [SEP] Diseases affecting the eye.


pleural effusion [SEP] A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sul

Pleural Effusion [SEP] Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a si


eosinophilia [SEP] n with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine tr

Eosinophilia [SEP] Abnormal increase of EOSINOPHILS in the blood, tissues or organs.


urinary abnormalities [SEP]  colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment. Light microscopy

Urinary Bladder Diseases [SEP] Pathological processes of the URINARY BLADDER.


sulphasalazine [SEP] ion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment. Light microscopy of a kidney biopsy revealed segment


segmental necrotizing glomerulonephritis [SEP] alazine treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase

Glomerulosclerosis, Focal Segmental [SEP] A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary


pleural effusions [SEP] idase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sul


fever [SEP] ssation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume o

Fever [SEP] An abnormal elevation of body temperature, usually as a result of a pathologic process.


chest pain [SEP] salazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusion

Chest Pain [SEP] Pressure, burning, or numbness in the chest.


steroid [SEP] ctive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil coun

Steroids [SEP] A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precurso


glomerulonephritis [SEP] ht microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase


phenytoin [SEP] Is phenytoin administration safe in a hypothermic child?

Phenytoin [SEP] An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mec


hypothermic [SEP] Is phenytoin administration safe in a hypothermic child?

Hypothermia [SEP] Lower than normal body temperature, especially in warm-blooded animals.


Chiari malformation [SEP] A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal

Arnold-Chiari Malformation [SEP] A group of congenital malformations involving the brainstem, cerebellum, upper spinal cord, and surrounding bony structures. Typ


hypothermic [SEP] ing anaesthesia and surgery, he inadvertently became moderately hypothermic. Intravenous phenytoin was administered during the later part o


phenytoin [SEP] ry, he inadvertently became moderately hypothermic. Intravenous phenytoin was administered during the later part of the surgery for seizu


seizure [SEP] ytoin was administered during the later part of the surgery for seizure prophylaxis. Following phenytoin administration, the patient de

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


bradycardia [SEP] ng phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline. The cardiac depressant

Bradycardia [SEP] Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. Th


atropine [SEP] , the patient developed acute severe bradycardia, refractory to atropine and adrenaline. The cardiac depressant actions of phenytoin and

Atropine [SEP] An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isome


adrenaline [SEP]  developed acute severe bradycardia, refractory to atropine and adrenaline. The cardiac depressant actions of phenytoin and hypothermia ca

Epinephrine [SEP] The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes


hypothermia [SEP] and adrenaline. The cardiac depressant actions of phenytoin and hypothermia can be additive. Administration of phenytoin in the presence of


Amisulpride [SEP] Amisulpride related tic-like symptoms in an adolescent schizophrenic.

sultopride [SEP]


tic-like symptoms [SEP] Amisulpride related tic-like symptoms in an adolescent schizophrenic.

Tic Disorders [SEP] Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythm


schizophrenic [SEP] Amisulpride related tic-like symptoms in an adolescent schizophrenic.

Schizophrenia [SEP] A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALL


Tic disorders [SEP] Tic disorders can be effectively treated by atypical antipsychotics such as r


risperidone [SEP] s can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone. However, there are two case report

Risperidone [SEP] A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has


olanzapine [SEP] ctively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone. However, there are two case reports that show

olanzapine [SEP]


ziprasidone [SEP]  by atypical antipsychotics such as risperidone, olanzapine and ziprasidone. However, there are two case reports that show tic-like symptom

ziprasidone [SEP]


tic-like symptoms [SEP]  and ziprasidone. However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatmen


quetiapine [SEP] ding motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who d

quetiapine [SEP]


clozapine [SEP]  phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed freq

Clozapine [SEP] A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system rec


schizophrenic [SEP] ent with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after


involuntary eye-blinking movements [SEP] present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The

Dyskinesias [SEP] Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underly


amisulpride [SEP] d frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The tic-like symptoms resolved com

sultopride [SEP]


psychosis [SEP] ed the dose of amisulpride down to 800 mg per day. However, her psychosis recurred after the dose reduction. We then placed her on an add

Psychoses, Substance-Induced [SEP] Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance.


aspirin [SEP] Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.

Aspirin [SEP] The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties a


acetylsalicylic acid [SEP] Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.


developmental anomalies [SEP] ti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenes

Abnormalities, Drug-Induced [SEP] Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is in


Aspirin [SEP] urs in rats given NSAIDs on specific days during organogenesis. Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1


acetylsalicylic acid [SEP] ts given NSAIDs on specific days during organogenesis. Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induc


ASA [SEP] cific days during organogenesis. Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces de


gastrointestinal toxicity [SEP] anogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA

Gastrointestinal Diseases [SEP] Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.


malformations [SEP] trointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used. METHODS: ASA


ventricular septal defects [SEP] RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hern

Heart Septal Defects, Ventricular [SEP] Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower


VSDs [SEP] uation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH


midline defects [SEP] gested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in r

Neural Tube Defects [SEP] Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during t


MDs [SEP] s induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbit


diaphragmatic hernia [SEP] lar septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, t

Hernias, Diaphragmatic, Congenital [SEP] Protrusion of abdominal structures into the THORAX as a result of embryologic defects in the DIAPHRAGM often present in the neon


DH [SEP] Ds) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the p


MD [SEP] s induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbi


VSD [SEP] uation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (D


hydrocephalus [SEP] SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats. Variations and malformations were similar w

Hydrocephalus [SEP] Excessive accumulation of cerebrospinal fluid within the cranium which may be associated with dilation of cerebral ventricles, I


Torsade de pointes [SEP] Torsade de pointes induced by metoclopramide in an elderly woman with preexisting

Torsades de Pointes [SEP] A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute


metoclopramide [SEP] Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branc

Metoclopramide [SEP] A dopamine D2 antagonist that is used as an antiemetic.


left bundle branch block [SEP] by metoclopramide in an elderly woman with preexisting complete left bundle branch block.

Bundle-Branch Block [SEP] A form of heart block in which the electrical stimulation of HEART VENTRICLES is interrupted at either one of the branches of BU


long QT syndrome [SEP] There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes. However, the torsadogenic potential of

Long QT Syndrome [SEP] A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by


torsade de pointes [SEP] owing list of drugs implicated in acquired long QT syndrome and torsade de pointes. However, the torsadogenic potential of metoclopramide, a commo


metoclopramide [SEP]  and torsade de pointes. However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been r


procainamide [SEP]  reported in the literature, despite its chemical similarity to procainamide. We report on a 92-year-old woman with preexisting complete lef

Procainamide [SEP] A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.


left bundle branch block [SEP] ide. We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral adm


cisapride [SEP] clopramide. This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously. These two episodes

Cisapride [SEP] A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, fun


erythromycin [SEP] is patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously. These two episodes were suppressed s

Erythromycin [SEP] A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active componen


Metoclopramide [SEP] ion that metoclopramide provokes torsade de pointes clinically. Metoclopramide should be used cautiously in patients with a risk of torsade de


Apomorphine [SEP] Apomorphine: an underutilized therapy for Parkinson's disease.

Apomorphine [SEP] A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poiso


Parkinson's disease [SEP] Apomorphine: an underutilized therapy for Parkinson's disease.

Parkinson Disease [SEP] A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency


Apomorphine [SEP] Apomorphine was the first dopaminergic drug ever used to treat symptoms of


Parkinson's disease [SEP]  was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as e


apomorphine [SEP] uctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A num


levodopa [SEP] tiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-

Levodopa [SEP] The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can b


dopamine [SEP] Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. Wh

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


dyskinesias [SEP] sociated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment ar

Dyskinesia, Drug-Induced [SEP] Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or


psychiatric [SEP] elated to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of ef

Mental Disorders [SEP] Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of tho


delirium [SEP] Fatal excited delirium following cocaine use: epidemiologic findings provide new evide

Delirium [SEP] A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instan


cocaine [SEP] Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms

Cocaine [SEP] An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinic


toxicity [SEP] iologic findings provide new evidence for mechanisms of cocaine toxicity.

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


cocaine [SEP] We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between


delirium [SEP] We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990. From a re